HBV Treatment in a Patient Who Will Be Receiving Immunosuppressive Therapy

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Apr 18

PMID 30992818

Citations 1

Authors

Jordan J Feld

Affiliations

Soon will be listed here.

Citing Articles

The Impact of Biologics for the Management of Inflammatory Bowel Disease on Liver Enzymes.

Aby E, Lake J, Vaughn B Clin Liver Dis (Hoboken). 2020; 16(5):212-217.

PMID: 33318791 PMC: 7727846. DOI: 10.1002/cld.1005.

References

Yeo W, Chan P, Hui P, Ho W, Lam K, Kwan W . Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003; 70(4):553-61. DOI: 10.1002/jmv.10430. View

Lau G, Yiu H, Fong D, Cheng H, Au W, Lai L . Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2004; 125(6):1742-9. DOI: 10.1053/j.gastro.2003.09.026. View

Knoll A, Boehm S, Hahn J, Holler E, Jilg W . Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004; 33(9):925-9. DOI: 10.1038/sj.bmt.1704457. View

Kempinska A, Kwak E, Angel J . Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis. 2005; 41(9):1277-82. DOI: 10.1086/496924. View

Yeo W, Johnson P . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43(2):209-20. DOI: 10.1002/hep.21051. View

Yim H, Lok A . Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1):S173-81. DOI: 10.1002/hep.20956. View

Feld J, Heathcote E . Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26(2):116-29. DOI: 10.1055/s-2006-939750. View

Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M . Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma. 2007; 48(2):431-3. DOI: 10.1080/10428190601059704. View

Rouphael N, Talati N, Rimland D . Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS. 2007; 21(6):771-4. DOI: 10.1097/QAD.0b013e3280ad47f5. View

10.

Hsu C, Hsiung C, Su I, Hwang W, Wang M, Lin S . A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008; 47(3):844-53. DOI: 10.1002/hep.22106. View

11.

Loomba R, Rowley A, Wesley R, Liang T, Hoofnagle J, Pucino F . Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148(7):519-28. PMC: 2729097. DOI: 10.7326/0003-4819-148-7-200804010-00008. View

12.

Weinbaum C, Williams I, Mast E, Wang S, Finelli L, Wasley A . Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008; 57(RR-8):1-20. View

13.

Yeo W, Chan T, Leung N, Lam W, Mo F, Chu M . Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2008; 27(4):605-11. DOI: 10.1200/JCO.2008.18.0182. View

14.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

15.

Lok A, Liang R, Chiu E, Wong K, Chan T, Todd D . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100(1):182-8. DOI: 10.1016/0016-5085(91)90599-g. View

16.

Artz A, Somerfield M, Feld J, Giusti A, Kramer B, Sabichi A . American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010; 28(19):3199-202. DOI: 10.1200/JCO.2010.30.0673. View

17.

Carroll M, Forgione M . Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010; 29(9):1021-9. DOI: 10.1007/s10067-010-1523-2. View

18.

Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M . Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010; 116(20):4769-76. DOI: 10.1002/cncr.25253. View

19.

Roche B, Samuel D . The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011; 31 Suppl 1:104-10. DOI: 10.1111/j.1478-3231.2010.02396.x. View

20.

Koo Y, Tay M, Teh Y, Teng D, Tan D, Tan I . Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011; 90(10):1219-23. DOI: 10.1007/s00277-011-1241-0. View